GlassScriptPhysician profile
Betty Zhang
NPI 1053833681
$29,436.29
in general payments reported to CMS, 2019-2025
22 companies · $7,206 in 2025
The $7,206 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,045 · 2020: $44.19 · 2021: $439 · 2022: $700 · 2023: $13K · 2024: $5,710 · 2025: $7,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,388 · Travel and Lodging: $4,122 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,522 · Food and Beverage: $2,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,351.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,387.50 |
| Travel and Lodging | $4,121.55 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,521.50 |
| Food and Beverage | $2,826.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $24,038.99 | 2023-2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $1,610.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $742.76 | 2021-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $427.44 | 2023-2025 | Izervay |
| Harrow Eye, LLC | $384.67 | 2025 | Triesence, Vevye |
| Janssen Scientific Affairs, LLC | $375.00 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $374.23 | 2022-2024 | Eylea Hd, Eylea |
| Genentech, INC. | $282.50 | 2021-2025 | Vabysmo |
| Allergan, INC. | $161.31 | 2019 | |
| Maculogix, INC. | $158.37 | 2021 | |
| Sun Pharmaceutical Industries INC. | $145.99 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $129.57 | 2019 | |
| Kala Pharmaceuticals, INC. | $122.34 | 2021 | |
| Biogen, INC. | $120.90 | 2022-2023 | |
| Abbvie INC. | $81.46 | 2023-2025 | Ozurdex |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $80.90 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $62.78 | 2022-2025 | Xipere |
| Coherus Oncology, INC. | $52.58 | 2022-2023 | |
| Genentech USA, INC. | $23.26 | 2025 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.82 | 2019 | |
| Sight Sciences, INC. | $20.70 | 2020 | |
| Ani Pharmaceuticals, INC. | $19.42 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betty Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.